Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy
Arqueros, Cristina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Gallardo, Alberto (Institut de Recerca Sant Pau)
Vidal, Silvia (Institut de Recerca Sant Pau)
Osuna Gómez, Rubén (Institut de Recerca Sant Pau)
Tibau Martorell, Ariadna (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Bell, Olga (Institut de Recerca Sant Pau)
Ramon y Cajal, Teresa (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Lerma Puertas, Enrique (Institut de Recerca Sant Pau)
Lobato-Delgado, Bárbara (Institut de Recerca Sant Pau)
Salazar, Juliana (Institut de Recerca Sant Pau)
Barnadas i Molins, Agustí (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neoadjuvant setting. Tumour tissue and peripheral blood samples were retrospectively collected from 118 patients, and sTILs were evaluated. Circulating exosomes and myeloid-derived suppressor cells were determined by flow cytometry. TIICs markers (CD4, CD8, CD20, CD1a, and CD68) were assessed immunohistochemically. High sTILs were significantly associated with pathological complete response (pCR; p = 0. 048) and event-free survival (EFS; p = 0. 027). High-CD68 cells were significantly associated with pCR in triple-negative (TN, p = 0. 027) and high-CD1a cells with EFS in luminal-B (p = 0. 012) BC. Cluster analyses of TIICs revealed two groups of tumours (C1 and C2) that had different immune patterns and clinical outcomes. An immunoscore based on clinicopathological variables was developed to identify high risk (C1) or low-risk (C2) patients. Additionally, cluster analyses revealed two groups of tumours for both luminal-B and TNBC. Our findings support the association of sTILs with pCR and show an immunological component in a subset of patients with HER2-negative BC. Our immunoscore may be useful for future escalation or de-escalation treatments.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Breast cancer ; Neoadjuvant chemotherapy ; Stromal tumour-infiltrating lymphocytes ; Tumour-infiltrating immune cells
Published in:	International journal of molecular sciences, Vol. 25 (february 2024) , ISSN 1422-0067

DOI: 10.3390/ijms25052627
PMID: 38473874

14 p, 1.6 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles